Q-omics provides the consensus-scored GPR137B profile across patient tissues and cancer cell-line models. GPR137B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GPR137B is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, GPR137B RNA expression shows 19,493 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where GPR137B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR137B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR137B survival associations across molecular data types. GPR137B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR137B RNA expression–survival associations across cancer types. High GPR137B expression shows unfavorable associations in ACC and SCLC, but favorable associations in KIRC, ESCA, PAAD and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GPR137B RNA expression.
This table summarizes GPR137B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GPR137B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR137B shows lower tumor expression in KICH and higher tumor expression in HNSC, STAD, COAD, KIRC and BRCA. The HNSC box plot shows higher GPR137B RNA expression in tumor versus normal tissue (log2 FC = +1.124, t-test p < 0.001).
This table shows molecular features associated with GPR137B in patient tissues and cancer cell lines. In patient samples, GPR137B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR137B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
